Bavarian Nordic A/S Announces Major Shareholder Notification from Johnson & Johnson Innovation - Inc.
(Thomson Reuters ONE) -
COPENHAGEN, Denmark, August 22, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) has received notification from Johnson & Johnson Innovation - JJDC, Inc.
(JJDC) pursuant to section 29 of the Danish Securities Trading Act, that JJDC,
after the subscription of 512,102 new shares in Bavarian Nordic, has increased
its ownership in Bavarian Nordic and now holds 1,844,086 shares in Bavarian
Nordic corresponding to 5.77 % of the share capital and voting rights in
Bavarian Nordic. JJDC is a wholly-owned subsidiary of Johnson & Johnson.
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the
development, manufacturing and commercialization of cancer immunotherapies and
vaccines for infectious diseases, based on the Company's live virus vaccine
platform. Through long-standing collaborations, including a collaboration with
the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for
infectious diseases, including the non-replicating smallpox vaccine,
IMVAMUNE(®), which is stockpiled for emergency use by the United States and
other governments. The vaccine is approved in the European Union (under the
trade name IMVANEX(®)) and in Canada. Bavarian Nordic and its strategic partner
Janssen are developing an Ebola vaccine regimen, and therapeutic vaccines for
HPV, HBV and HIV. Additionally, in collaboration with the National Cancer
Institute, Bavarian Nordic has developed a portfolio of active cancer
immunotherapies, including PROSTVAC(®), which is currently in Phase 3 clinical
development for the treatment of advanced prostate cancer. The company has
partnered with Bristol-Myers Squibb for the potential commercialization of
PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on
Twitter (at)bavariannordic.
Contacts
Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43
Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271
Company Announcement no. 24 / 2017
2017-24-en:
http://hugin.info/100065/R/2128584/812932.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 22.08.2017 - 18:08 Uhr
Sprache: Deutsch
News-ID 557434
Anzahl Zeichen: 2712
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 354 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic A/S Announces Major Shareholder Notification from Johnson & Johnson Innovation - Inc."
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
